Login Register Cart 0
Generic placeholder image

Recent Patents on Nanotechnology

Editor-in-Chief

ISSN (Print): 1872-2105
ISSN (Online): 2212-4020

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

A Comprehensive Review of Therapeutic Approaches Available for the Treatment of Dermatitis

Author(s): Apoorva Singh and Nimisha*

Volume 16, Issue 3, 2022

Published on: 13 January, 2022

Page: [172 - 197] Pages: 26

DOI: 10.2174/1872210515666210806143015

Price: $65

Abstract

Background: Dermatitis or eczema is a prevalent skin disorder worldwide and is also very common as a pediatric inflammatory skin disorder. Its succession gets worse with the multiple comorbidities which exhibit mechanisms that are poorly understood. Its management further becomes a challenge due to the limited effective treatment options available. However, the Novel Drug Delivery Systems (NDDS) along with new targeting strategies can easily bypass the issues associated with dermatitis management. If we compare the active constituents against phytoconstituents effective against dermatitis then phytoconstituents can be perceived to be more safe and gentle.

Objective: Administration of NDDS of plant extract or actives displays improved absorption behavior, which helps them to permeate through lipid-rich biological membrane leading to increased bioavailability. The newer efficient discoveries related to eczema can face various exploitations. This can be intervened by the subjection of patent rights, which not only safeguard the novel works of individual(s) but also give them the opportunity to share details of their inventions with people globally.

Conclusion: The present review focuses on the available research about the use of nanoformulations in the topical delivery. It further elaborates the use of different animal models as the basis to characterize the different features of dermatitis. The review also highlights the recent nanoformulations which have the ability to amplify the delivery of active agents through their incorporation in transfersomes, ethosomes, niosomes or phytosomes, etc.

Keywords: Dermatitis, nanoformulations, NDDS, phytoconstituents, patent, targeting, skin disorder.

« Previous Next »
Graphical Abstract

[1]
Marks JG, Miller JJ. Lookingbill and marks' principles of dermatology. In: e-book.Elsevier Health Sciences. 6th ed. 2017; pp. 336.
[2]
Breuer K, Kapp A, Werfel T. Bacterial infections and atopic dermatitis. Allergy 2001 November; 56(11): 1034-41.
[http://dx.doi.org/10.1034/j.1398-9995.2001.00146.x] [PMID: 11703215]
[3]
Phelps RG, Miller MK, Singh F. The varieties of "eczema": Clinicopathologic correlation. Clin Dermatol. 2003 Mar-Apr; 21(2):95- 100. Available from: https://dermnetnz.org/topics/eczema-pathology/ cited May 25, 2021.
[4]
Rakel D. Integrative Medicine. In: E-book. Elsevier Health Sciences. 4th ed. 2017; pp. 1152.
[5]
Frazier W, Bhardwaj N. Atopic dermatitis: Diagnosis and treatment. Am Fam Physician 2020 May 15; 101(10): 590-8.
[PMID: 32412211]
[6]
Nakajima S, Nomura T, Common J, Kabashima K. Insights into atopic dermatitis gained from genetically defined mouse models. J Allergy Clin Immunol 2019 January 01; 143(1): 13-25.
[http://dx.doi.org/10.1016/j.jaci.2018.11.014] [PMID: 30612664]
[7]
Boguniewicz M, Leung DY. Atopic dermatitis: A disease of altered skin barrier and immune dysregulation. Immunol Rev 2011 June 20; 242(1): 233-46.
[http://dx.doi.org/10.1111/j.1600-065X.2011.01027.x] [PMID: 21682749]
[8]
Bains SN, Nash P, Fonacier L. Irritant contact dermatitis. Clin Rev Allergy Immunol 2019; 56(1): 99-109.
[http://dx.doi.org/10.1007/s12016-018-8713-0] [PMID: 30293200]
[9]
Borda LJ, Perper M, Keri JE. Treatment of seborrheic dermatitis: A comprehensive review. J Dermatolog Treat 2019; 30(2): 158-69.
[http://dx.doi.org/10.1080/09546634.2018.1473554] [PMID: 29737895]
[10]
Pugliese DJ. Stasis Dermatitis.Inpatient Dermatology. Cham: Springer 2018 November 03; pp. 379-82.
[http://dx.doi.org/10.1007/978-3-319-18449-4_76]
[11]
Reich D, Psomadakis CE, Buka B. Nummular Eczema. In: Top 50 Dermatology Case Studies for Primary Care. Springer Cham 2017; pp. 167-72.
[http://dx.doi.org/10.1007/978-3-319-18627-6_27]
[12]
Nishizawa A. Dyshidrotic eczema and its relationship to metal allergy. Perspiration Research 2016. Karger Publishers 2016; 51: pp. 80-5.
[http://dx.doi.org/10.1159/000446785]
[13]
Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract 2020 January; 8(1): 91-101.
[http://dx.doi.org/10.1016/j.jaip.2019.06.044] [PMID: 31474543]
[14]
Kahraman E, Aydilek N, Güngör S. Recent Approaches on Novel Topical Delivery Systems for Atopic Dermatitis Treatment. Recent Pat Drug Deliv Formul 2020; 14(3): 191-200.
[http://dx.doi.org/10.2174/1872211314999200819152450] [PMID: 32819264]
[15]
Silverberg NB, Durán-McKinster C. Special considerations for therapy of pediatric atopic dermatitis. Dermatol Clin 2017 July; 35(3): 351-63.
[http://dx.doi.org/10.1016/j.det.2017.02.008] [PMID: 28577804]
[16]
Sundaresan S, Migden MR, Silapunt S. Stasis dermatitis: pathophysiology, evaluation, and management. Am J Clin Dermatol 2017 January 06; 18(3): 383-90.
[http://dx.doi.org/10.1007/s40257-016-0250-0] [PMID: 28063094]
[17]
Paller AS, Spergel JM, Mina-Osorio P, Irvine AD. The atopic march and atopic multimorbidity: Many trajectories, many pathways. J Allergy Clin Immunol 2019 January 01; 143(1): 46-55.
[http://dx.doi.org/10.1016/j.jaci.2018.11.006] [PMID: 30458183]
[18]
Lyons JJ, Milner JD, Stone KD. Atopic dermatitis in children: clinical features, pathophysiology, and treatment. Immunology and Allergy Clinics 2015 February; 35(1): 161-83.
[http://dx.doi.org/10.1016/j.iac.2014.09.008] [PMID: 25459583]
[19]
Souto EB, Dias-Ferreira J, Oliveira J, et al. Trends in Atopic Dermatitis-From Standard Pharmacotherapy to Novel Drug Delivery Systems. Int J Mol Sci 2019 November 12; 20(22): 5659.
[http://dx.doi.org/10.3390/ijms20225659] [PMID: 31726723]
[20]
Nesterova AP, Yuryev A, Klimov EA, et al. Disease pathways: An atlas of human disease signaling pathways. Elsevier. 1st ed 2019; p. 732.
[21]
Lalan M, Baweja J, Misra A. Atopic dermatitis: Drug delivery approaches in disease management. Critical Reviews™ in Therapeutic Drug Carrier Systems 2015; 32(4): 323-61.
[22]
Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell 2017 September 21; 171(1): 217-228.e13.
[http://dx.doi.org/10.1016/j.cell.2017.08.006] [PMID: 28890086]
[23]
Nomura T, Honda T, Kabashima K. Multipolarity of cytokine axes in the pathogenesis of atopic dermatitis in terms of age, race, species, disease stage and biomarkers. Int Immunol 2018 September; 30(9): 419-28.
[http://dx.doi.org/10.1093/intimm/dxy015] [PMID: 29518197]
[24]
Available from: https://www.thesoaphaven.com/eczema-psoriasis/eczema-causes/attachment/39703452-skin-showing-changes-due-to-dermatitis-labeled/
[25]
Tsakok T, Woolf R, Smith CH, Weidinger S, Flohr C. Atopic dermatitis: the skin barrier and beyond. Br J Dermatol 2019 March; 180(3): 464-74.
[http://dx.doi.org/10.1111/bjd.16934] [PMID: 29969827]
[26]
Archer CB. Atopic eczema. Medicine (Baltimore) 2013 June; 41(6): 341-4.
[http://dx.doi.org/10.1016/j.mpmed.2013.04.002]
[27]
Sugita K, Akdis CA. Recent developments and advances in atopic dermatitis and food allergy. Allergol Int 2020 April; 69(2): 204-14.
[http://dx.doi.org/10.1016/j.alit.2019.08.013] [PMID: 31648922]
[28]
Grillo M, Gassner L, Marshman G, Dunn S, Hudson P. Pediatric atopic eczema: the impact of an educational intervention. Pediatr Dermatol 2006 Sepetember/October; 23(5): 428-36.
[http://dx.doi.org/10.1111/j.1525-1470.2006.00277.x] [PMID: 17014636]
[29]
Ersser SJ, Cowdell F, Latter S, et al. Psychological and educational interventions for atopic eczema in children. Cochrane Database of Systematic Reviews 2014; (1):
[http://dx.doi.org/10.1002/14651858.CD004054.pub3]
[30]
Staab D, Diepgen TL, Fartasch M, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ 2006 April 20; 332(7547): 933-8.
[http://dx.doi.org/10.1136/bmj.332.7547.933] [PMID: 16627509]
[31]
Jones SM. Triggers of atopic dermatitis. Immunology and Allergy Clinics 2002 February; 22(1): 55-72.
[http://dx.doi.org/10.1016/S0889-8561(03)00069-9]
[32]
Sicherer SH, Sampson HA. Food hypersensitivity and atopic dermatitis: pathophysiology, epidemiology, diagnosis, and management. J Allergy Clin Immunol 1999 September; 104(3 Pt 2): S114-22.
[http://dx.doi.org/10.1016/S0091-6749(99)70053-9] [PMID: 10482862]
[33]
Lodén M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol 2003; 4(11): 771-88.
[http://dx.doi.org/10.2165/00128071-200304110-00005] [PMID: 14572299]
[34]
Takagi Y, Ning X, Takahashi A, et al. The efficacy of a pseudo-ceramide and eucalyptus extract containing lotion on dry scalp skin. Clin Cosmet Investig Dermatol 2018 April 6; 11: 141-8.
[http://dx.doi.org/10.2147/CCID.S158428] [PMID: 29670385]
[35]
Devillers AC, Oranje AP. Efficacy and safety of ‘wet-wrap’ dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: A critical review of the literature. Br J Dermatol 2006 February 20; 154(4): 579-85.
[http://dx.doi.org/10.1111/j.1365-2133.2006.07157.x] [PMID: 16536797]
[36]
Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2001 January; 4(37): 1-191.
[http://dx.doi.org/10.3310/hta4370] [PMID: 11134919]
[37]
Hussain Z, Sahudin S, Thu HE, Shuid AN, Bukhari SN, Kumolosasi E. Recent advances in pharmacotherapeutic paradigm of mild to recalcitrant atopic dermatitis. Critical Reviews™ in Therapeutic Drug Carrier Systems 2016; 33(3)
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.2016015219]
[38]
Spergel JM, Leung DY. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr Allergy Asthma Rep 2006 July; 6(4): 270-4.
[http://dx.doi.org/10.1007/s11882-006-0059-7] [PMID: 16822378]
[39]
Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med 2005 June 02; 352(22): 2314-24.
[http://dx.doi.org/10.1056/NEJMcp042803] [PMID: 15930422]
[40]
Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007 March 22; 21(5): 606-19.
[http://dx.doi.org/10.1111/j.1468-3083.2006.02023.x] [PMID: 17447974]
[41]
Schram ME, Borgonjen RJ, Bik CM, van der Schroeff JG, van Everdingen JJ, Spuls PI. Off-label use of azathioprine in dermatology: A systematic review. Arch Dermatol 2011; 147(4): 474-88.
[http://dx.doi.org/10.1001/archdermatol.2011.79] [PMID: 21482898]
[42]
Patrizi A, Raone B, Ravaioli GM. Management of atopic dermatitis: safety and efficacy of phototherapy. Clin Cosmet Investig Dermatol 2015 May 28; 8: 511-20.
[http://dx.doi.org/10.2147/CCID.S87987] [PMID: 26491366]
[43]
Nagpal S, Lu J, Boehm MF. Vitamin D analogs: mechanism of action and therapeutic applications. Curr Med Chem 2001; 8(13): 1661-79.
[http://dx.doi.org/10.2174/0929867013371950] [PMID: 11562285]
[44]
Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006 January; 54(1): 1-15.
[http://dx.doi.org/10.1016/j.jaad.2005.01.010] [PMID: 16384751]
[45]
Nesbitt LT Jr. Minimizing complications from systemic glucocorticosteroid use. Dermatol Clin 1995 October; 13(4): 925-39.
[http://dx.doi.org/10.1016/S0733-8635(18)30055-X] [PMID: 8785896]
[46]
Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatr Drugs 2013 April 03; 15(4): 303-10.
[http://dx.doi.org/10.1007/s40272-013-0013-9] [PMID: 23549982]
[47]
Herman SM, Vender RB. Antihistamines in the treatment of dermatitis. J Cutan Med Surg 2003 November 01; 7(6): 467-73.
[http://dx.doi.org/10.1177/120347540300700608] [PMID: 15926215]
[48]
Boguniewicz M, Nicol N. Conventional therapy for atopic dermatitis. Immunology and Allergy Clinics 2002 February; 22(1): 107-24.
[http://dx.doi.org/10.1016/S0889-8561(03)00072-9]
[49]
Meagher LJ, Wines NY, Cooper AJ. Atopic dermatitis: review of immunopathogenesis and advances in immunosuppressive therapy. Australas J Dermatol 2002 November 29; 43(4): 247-54.
[http://dx.doi.org/10.1046/j.1440-0960.2002.00610.x] [PMID: 12423430]
[50]
Rodenbeck DL, Silverberg JI, Silverberg NB. Phototherapy for atopic dermatitis. Clin Dermatol 2016 September-October; 34(5): 607-13.
[http://dx.doi.org/10.1016/j.clindermatol.2016.05.011] [PMID: 27638440]
[51]
Lehmann B, Querings K, Reichrath J. Vitamin D and skin: new aspects for dermatology. Exp Dermatol 2004 October 26; 13(Suppl. 4): 11-5.
[http://dx.doi.org/10.1111/j.1600-0625.2004.00257.x] [PMID: 15507106]
[52]
Shinde NG, Aloorkar NH, Kulkarni AS. Recent advances in vesicular drug delivery system. Res J Pharm Dos Forms Technol 2014 April-June; 6(2): 110-20.
[53]
Razdan K, Sinha VR, Singh KK. New Paradigms in the Treatment of Skin Infections: Lipid Nanocarriers to the Rescue. In: Nanomedicine for Bioactives. Singapore: Springer 2020; pp. 317-39.
[54]
Bansal S, Kashyap CP, Aggarwal G, Harikumar SL. A comparative review on vesicular drug delivery system and stability issues. Int J Res Pharm Chem 2012; 2(3): 704-13.
[55]
Crommelin DJA, Van Hoogevest P, Storm G. The role of liposomes in Clinical Nanomedicine development. What now? Now what? J Control Release 2020; 318: 256-63.
[http://dx.doi.org/10.1016/j.jconrel.2019.12.023] [PMID: 31846618]
[56]
Dave V, Sharma S, Yadav RB, Agarwal U. Herbal. Liposome for the topical delivery of ketoconazole for the effective treatment of seborrheic dermatitis. Appl Nanosci 2017; 7(8): 973-87.
[http://dx.doi.org/10.1007/s13204-017-0634-3]
[57]
Jahn A, Song CK, Balakrishnan P, et al. AAPE proliposomes for topical atopic dermatitis treatment. J Microencapsul 2014; 31(8): 768-73.
[http://dx.doi.org/10.3109/02652048.2014.932027] [PMID: 25090594]
[58]
Jung SH, Cho YS, Jun SS, et al. Topical application of liposomal cobalamin hydrogel for atopic dermatitis therapy. Pharmazie 2011; 66(6): 430-5.
[PMID: 21699082]
[59]
Patel SS, Patel MS, Salampure S, et al. Development and evaluation of liposomes for topical delivery of tacrolimus (Fk-506). J Sci Re 2010; 2(3): 585.
[http://dx.doi.org/10.3329/jsr.v2i3.3258]
[60]
Lim GJ, Ishiuji Y, Dawn A, et al. in vitro and in vivo Characterization of a novel liposomal butorphanol formulation for treatment of pruritus. Acta Derm Venereol 2008; 88(4): 327-30.
[PMID: 18709299]
[61]
Ramkar S, Sah AK, Bhuwane N, et al. Nano-Lipidic Carriers as a Tool for Drug Targeting to the Pilosebaceous Units. Curr Pharm Des 2020; 26(27): 3251-68.
[http://dx.doi.org/10.2174/1381612826666200515133142] [PMID: 32410556]
[62]
Pandey V, Golhani D, Shukla R. Ethosomes: versatile vesicular carriers for efficient transdermal delivery of therapeutic agents. Drug Deliv 2015; 22(8): 988-1002.
[http://dx.doi.org/10.3109/10717544.2014.889777] [PMID: 24580572]
[63]
El-Menshawe SF, Sayed OM, Abou-Taleb HA, El Tellawy N. Skin permeation enhancement of nicotinamide through using fluidization and deformability of positively charged ethosomal vesicles: A new approach for treatment of atopic eczema. J Drug Deliv Sci Technol 2019; 52: 687-701.
[http://dx.doi.org/10.1016/j.jddst.2019.05.038]
[64]
Goindi S, Dhatt B, Kaur A. Ethosomes-based topical delivery system of antihistaminic drug for treatment of skin allergies. J Microencapsul 2014; 31(7): 716-24.
[http://dx.doi.org/10.3109/02652048.2014.918667] [PMID: 24963956]
[65]
Li G, Fan Y, Fan C, et al. Tacrolimus-loaded ethosomes: Physicochemical Characterization and in vivo evaluation. Eur J Pharm Biopharm 2012; 82(1): 49-57.
[http://dx.doi.org/10.1016/j.ejpb.2012.05.011] [PMID: 22705640]
[66]
Maheshwari RG, Tekade RK, Sharma PA, et al. Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: A comparative assessment. Saudi Pharm J 2012; 20(2): 161-70.
[http://dx.doi.org/10.1016/j.jsps.2011.10.001] [PMID: 23960788]
[67]
Li G, Fan C, Li X, et al. Preparation and in vitro evaluation of tacrolimus-loaded ethosomes. Sci Wo J 2012; 2012: 874053.
[http://dx.doi.org/10.1100/2012/874053] [PMID: 22629219]
[68]
Garg V, Singh H, Bimbrawh S, et al. Ethosomes and transfersomes: principles, perspectives and practices. Curr Drug Deliv 2017; 14(5): 613-33.
[http://dx.doi.org/10.2174/1567201813666160520114436] [PMID: 27199229]
[69]
Barone A, Cristiano MC, Cilurzo F, et al. Ammonium glycyrrhizate skin delivery from ultradeformable liposomes: A novel use as an anti-inflammatory agent in topical drug delivery. Colloids Surf B Biointerfaces 2020; 193: 111152.
[http://dx.doi.org/10.1016/j.colsurfb.2020.111152] [PMID: 32535351]
[70]
Chauhan S, Gulati N, Nagaich U. Fabrication and evaluation of ultra deformable vesicles for atopic dermatitis as topical delivery. Int J of Poly Mat and Poly Biomat 2019; 68(5): 266-77.
[http://dx.doi.org/10.1080/00914037.2018.1443932]
[71]
Goindi S, Kumar G, Kaur A. Novel flexible vesicles based topical formulation of levocetirizine: In vivo evaluation using oxazolone-induced atopic dermatitis in murine model. J Liposome Res 2014; 24(3): 249-57.
[http://dx.doi.org/10.3109/08982104.2014.899365] [PMID: 24646413]
[72]
Goindi S, Kumar G, Kumar N, Kaur A. Development of novel elastic vesicle-based topical formulation of cetirizine dihydrochloride for treatment of atopic dermatitis. AAPS PharmSciTech 2013; 14(4): 1284-93.
[http://dx.doi.org/10.1208/s12249-013-0017-3] [PMID: 23959702]
[73]
Kang MJ, Eum JY, Jeong MS, et al. Tat peptide-admixed elastic liposomal formulation of hirsutenone for the treatment of atopic dermatitis in NC/Nga mice. Int J Nanomedicine 2011; 6: 2459-67.
[PMID: 22072881]
[74]
Hamishehkar H, Rahimpour Y, Kouhsoltani M. Niosomes as a propitious carrier for topical drug delivery. Expert Opin Drug Deliv 2013; 10(2): 261-72.
[http://dx.doi.org/10.1517/17425247.2013.746310] [PMID: 23252629]
[75]
Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery—an overview. Acta Pharm Sin B 2011; 1(4): 208-19.
[http://dx.doi.org/10.1016/j.apsb.2011.09.002]
[76]
Kassem AA, Abd El-Alim SH, Asfour MH. Enhancement of 8-methoxypsoralen topical delivery via nanosized niosomal vesicles: Formulation development, in vitro and in vivo evaluation of skin deposition. Int J Pharm 2017; 517(1-2): 256-68.
[http://dx.doi.org/10.1016/j.ijpharm.2016.12.018] [PMID: 27956194]
[77]
Marianecci C, Rinaldi F, Mastriota M, et al. Anti-inflammatory activity of novel ammonium glycyrrhizinate/niosomes delivery system: human and murine models. J Control Release 2012; 164(1): 17-25.
[http://dx.doi.org/10.1016/j.jconrel.2012.09.018] [PMID: 23041542]
[78]
Shirsand S, Para M, Nagendrakumar D, Kanani K, Keerthy D. Formulation and evaluation of Ketoconazole niosomal gel drug delivery system. Int J Pharm Investig 2012; 2(4): 201-7.
[http://dx.doi.org/10.4103/2230-973X.107002] [PMID: 23580936]
[79]
Sankar V, Praveen C, Prasanth KG, Srinivas CR, Ruckmann K. Formulation and evaluation of a proniosome hydrocortisone gel in comparison with a commercial cream. Pharmazie 2009; 64(11): 731-4.
[PMID: 20099517]
[80]
Balakrishnan P, Shanmugam S, Lee WS, et al. Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery. Int J Pharm 2009; 377(1-2): 1-8.
[http://dx.doi.org/10.1016/j.ijpharm.2009.04.020] [PMID: 19394413]
[81]
Permana AD, Utami RN, Courtenay AJ, Manggau MA, Donnelly RF, Rahman L. Phytosomal nanocarriers as platforms for improved delivery of natural antioxidant and photoprotective compounds in propolis: An approach for enhanced both dissolution behaviour in biorelevant media and skin retention profiles. J Photochem Photobiol B 2020; 205: 111846.
[http://dx.doi.org/10.1016/j.jphotobiol.2020.111846] [PMID: 32151785]
[82]
Kapoor B, Gupta R, Gulati M, Singh SK, Khursheed R, Gupta M. The Why, Where, Who, How, and What of the vesicular delivery systems. Adv Colloid Interface Sci 2019; 271: 101985.
[http://dx.doi.org/10.1016/j.cis.2019.07.006] [PMID: 31351415]
[83]
Nasr M, Younes H, Abdel-Rashid RS. Formulation and evaluation of cubosomes containing colchicine for transdermal delivery. Drug Deliv Transl Res 2020; 10(5): 1302-13.
[http://dx.doi.org/10.1007/s13346-020-00785-6] [PMID: 32399604]
[84]
Gopinath D, Ravi D, Rao BR, Apte SS, Renuka D, Rambhau D. Ascorbyl palmitate vesicles (Aspasomes): Formation, characterization and applications. Int J Pharm 2004; 271(1-2): 95-113.
[http://dx.doi.org/10.1016/j.ijpharm.2003.10.032] [PMID: 15129977]
[85]
Jia Y, Akache B, Deschatelets L, et al. A comparison of the immune responses induced by antigens in three different archaeosome-based vaccine formulations. Int J Pharm 2019; 561: 187-96.
[http://dx.doi.org/10.1016/j.ijpharm.2019.02.041] [PMID: 30836154]
[86]
El-Nabarawi MA, Shamma RN, Farouk F, et al. Bilosomes as a novel carrier for the cutaneous delivery for dapsone as a potential treatment of acne: preparation, characterization and in vivo skin deposition assay. J Liposome Res 2020; 30(1): 1-11.
[http://dx.doi.org/10.1080/08982104.2019.1577256] [PMID: 31010357]
[87]
Asfour MH. Advanced trends in protein and peptide drug delivery: A special emphasis on aquasomes and microneedles techniques. Drug Deliv Transl Res 2021; 11(1): 1-23.
[http://dx.doi.org/10.1007/s13346-020-00746-z] [PMID: 32337668]
[88]
Abdel-Messih HA, Ishak RAH, Geneidi AS, et al. Tailoring novel soft nano-vesicles ‘Flexosomes’ for enhanced transdermal drug delivery: Optimization, characterization and comprehensive ex vivo - in vivo evaluation. Int J Pharm 2019; 560: 101-15.
[http://dx.doi.org/10.1016/j.ijpharm.2019.01.072] [PMID: 30753931]
[89]
Lakshmi P, Kalpana B, Prasanthi D. Invasomes-novel vesicular carriers for enhanced skin permeation. Syst Rev Phar 2013; 4(1): 26.
[http://dx.doi.org/10.4103/0975-8453.135837]
[90]
Sharma A, Arora S. Formulation and in vitro evaluation of ufasomes for dermal administration of methotrexate. Int Sch Re Not 2012; 2012.
[http://dx.doi.org/10.5402/2012/873653]
[91]
Khogta S, Patel J, Barve K, Londhe V. Herbal nano-formulations for topical delivery. J Herb Med 2020; 20: 100300.
[http://dx.doi.org/10.1016/j.hermed.2019.100300]
[92]
Chaubey R, Srivastava N, Singh A. Enhancement of Dissolution Rate of Quercetin Using Solid Dispersion Approach: in vitro and in vivo Evaluation. Nanosci Nanotechnol Asia 2020; 10(3): 330-49.
[http://dx.doi.org/10.2174/2210681209666190919095128]
[93]
Nimisha Fatima Z. Formulation and Performance evaluation of Berberis aristata extract loaded ethosomal gel. Asian Journal of Pharmaceutics (AJP): Free full text articles from Asian J Pharm. 2017; 11(03)
[94]
Nimisha DA, Rizvi DA, Fatima Z, et al. Antipsoriatic and anti-inflammatory studies of Berberis aristata extract loaded nanovesicular gels. Pharmacogn Mag 2017; 13(Suppl. 3): S587-94.
[http://dx.doi.org/10.4103/pm.pm_210_17] [PMID: 29142419]
[95]
Nimisha FZ, Kaur CD. A review on potential of novel vesicular carriers for carrying herbal drugs in the treatment of dermatological disorders. Journal of Atoms and Molecules 2016; 6(3): 987.
[96]
Chen X, Zhu C, Zhang Y, et al. Antipruritic Effect of Ethyl Acetate Extract from Fructus cnidii in Mice with 2,4-Dinitrofluorobenzene-Induced Atopic Dermatitis. Evid Based Complement Alternat Med 2020; 2020: 6981386.
[PMID: 32454868]
[97]
Ngo HTT, Fang M, Hwang E, et al. Inhibitory Effects of Urtica thunbergiana Ethanol Extract on Atopic Dermatitis-Induced NC/Nga Mice. Antioxidants 2020; 9(3): 197.
[http://dx.doi.org/10.3390/antiox9030197] [PMID: 32111037]
[98]
Jeong JH, Back SK, An JH, et al. Topical film prepared with Rhus verniciflua extract-loaded pullulan hydrogel for atopic dermatitis treatment. J Biomed Mater Res B Appl Biomater 2019; 107(7): 2325-34.
[http://dx.doi.org/10.1002/jbm.b.34325] [PMID: 30697924]
[99]
Cha KJ, Kashif A, Hong MH, Kim G, Lee JS, Kim IS. Poncirus Trifoliata (L.) Raf. Extract Inhibits the Development of Atopic Dermatitis-like Lesions in Human Keratinocytes and NC/Nga mice. Int J Med Sci 2019; 16(8): 1116-22.
[http://dx.doi.org/10.7150/ijms.34323] [PMID: 31523174]
[100]
Yang JH, Lee E, Lee B, et al. Ethanolic Extracts of Artemisia apiacea Hance Improved Atopic Dermatitis-Like Skin Lesions in vivo and Suppressed TNF-Alpha/IFN-Gamma–Induced Proinflammatory Chemokine Production in vitro. Nutrients 2018; 10(7): 806.
[http://dx.doi.org/10.3390/nu10070806]
[101]
Jo GH, Kim SN, Kim MJ, et al. Protective effect of Paeoniae radix alba root extract on immune alterations in mice with atopic dermatitis. J Toxicol Environ Health A 2018; 81(12): 502-11.
[http://dx.doi.org/10.1080/15287394.2018.1460785] [PMID: 29630468]
[102]
Abbasi S, Kamalinejad M, Babaie D, et al. A new topical treatment of atopic dermatitis in pediatric patients based on Ficus carica L. A randomized, placebo-controlled clinical trial. Comp Ther Med 2017; 35: 85-91.
[http://dx.doi.org/10.1016/j.ctim.2017.10.003] [PMID: 29154073]
[103]
Kang SY, Jung HW, Nam JH, et al. Effects of the fruit extract of Tribulus terrestris on skin inflammation in mice with oxazolone-induced atopic dermatitis through regulation of calcium channels, Orai-1 and TRPV3, and mast cell activation. Evid Based Complement Alternat Med 2017; 2017: 8312946.
[http://dx.doi.org/10.1155/2017/8312946] [PMID: 29348776]
[104]
Jung AR, Ahn SH, Park IS, et al. Douchi (fermented Glycine max Merr.) alleviates atopic dermatitis-like skin lesions in NC/Nga mice by regulation of PKC and IL-4. BMC Complement Altern Med 2016; 16(1): 416.
[http://dx.doi.org/10.1186/s12906-016-1394-4] [PMID: 27776525]
[105]
Yang JH, Yoo JM, Cho WK, Ma JY. Ethanol extract of sanguisorbae radix inhibits mast cell degranulation and suppresses 2, 4-dinitrochlorobenzene-induced atopic dermatitis-like skin lesions. Mediators of inflammation 2016; 2016
[106]
Ha H, Lim HS, Lee MY, et al. Luffa cylindrica suppresses development of Dermatophagoides farinae-induced atopic dermatitis-like skin lesions in Nc/Nga mice. Pharm Biol 2015; 53(4): 555-62.
[http://dx.doi.org/10.3109/13880209.2014.932392] [PMID: 25327534]
[107]
Shin YK, Son HU, Kim JM, Heo JC, Lee SH, Kim JG. Cinnamomum cassia bark produced by solid-state fermentation with Phellinus baumii has the potential to alleviate atopic dermatitis-related symptoms. Int J Mol Med 2015; 35(1): 187-94.
[http://dx.doi.org/10.3892/ijmm.2014.2006] [PMID: 25406033]
[108]
Gutermuth J, Ollert M, Ring J, Behrendt H, Jakob T. Mouse models of atopic eczema critically evaluated. Int Arch Allergy Immunol 2004; 135(3): 262-76.
[http://dx.doi.org/10.1159/000082099] [PMID: 15542938]
[109]
Jin H, He R, Oyoshi M, Geha RS. Animal models of atopic dermatitis. J Invest Dermatol 2009; 129(1): 31-40.
[http://dx.doi.org/10.1038/jid.2008.106] [PMID: 19078986]
[110]
Spergel JM, Mizoguchi E, Brewer JP, Martin TR, Bhan AK, Geha RS. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest 1998; 101(8): 1614-22.
[http://dx.doi.org/10.1172/JCI1647] [PMID: 9541491]
[111]
Huang CH, Kuo IC, Xu H, Lee YS, Chua KY. Mite allergen induces allergic dermatitis with concomitant neurogenic inflammation in mouse. J Invest Dermatol 2003; 121(2): 289-93.
[http://dx.doi.org/10.1046/j.1523-1747.2003.12356.x] [PMID: 12880420]
[112]
Shiohara T, Hayakawa J, Mizukawa Y. Animal models for atopic dermatitis: Are they relevant to human disease? J Dermatol Sci 2004; 36(1): 1-9.
[http://dx.doi.org/10.1016/j.jdermsci.2004.02.013] [PMID: 15488700]
[113]
Li XM, Kleiner G, Huang CK, et al. Murine model of atopic dermatitis associated with food hypersensitivity. J Allergy Clin Immunol 2001; 107(4): 693-702.
[http://dx.doi.org/10.1067/mai.2001.114110] [PMID: 11295660]
[114]
Matsuda H, Watanabe N, Geba GP, et al. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 1997; 9(3): 461-6.
[http://dx.doi.org/10.1093/intimm/9.3.461] [PMID: 9088984]
[115]
Gao XK, Nakamura N, Fuseda K, Tanaka H, Inagaki N, Nagai H. Establishment of allergic dermatitis in NC/Nga mice as a model for severe atopic dermatitis. Biol Pharm Bull 2004; 27(9): 1376-81.
[http://dx.doi.org/10.1248/bpb.27.1376] [PMID: 15340222]
[116]
Watanabe O, Natori K, Tamari M, Shiomoto Y, Kubo S, Nakamura Y. Significantly elevated expression of PF4 (platelet factor 4) and eotaxin in the NOA mouse, a model for atopic dermatitis. J Hum Genet 1999; 44(3): 173-6.
[http://dx.doi.org/10.1007/s100380050136] [PMID: 10319581]
[117]
Yoshioka T, Hikita I, Matsutani T, et al. DS-Nh as an experimental model of atopic dermatitis induced by Staphylococcus aureus producing staphylococcal enterotoxin C. Immunology 2003; 108(4): 562-9.
[http://dx.doi.org/10.1046/j.1365-2567.2003.01588.x] [PMID: 12667219]
[118]
Pfister H, Ollert M, Fröhlich LF, et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 2004; 104(5): 1411-8.
[http://dx.doi.org/10.1182/blood-2004-01-0267] [PMID: 15150076]
[119]
Tani S, Noguchi M, Hosoda Y, Sugibayasi K, Morimoto Y. Characteristics of spontaneous erythema appeared in hairless rats. Exp Anim 1998; 47(4): 253-6.
[http://dx.doi.org/10.1538/expanim.47.253] [PMID: 10067168]
[120]
Chan LS, Robinson N, Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: An experimental animal model to study atopic dermatitis. J Invest Dermatol 2001; 117(4): 977-83.
[http://dx.doi.org/10.1046/j.0022-202x.2001.01484.x] [PMID: 11676841]
[121]
Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004; 5(7): 752-60.
[http://dx.doi.org/10.1038/ni1084] [PMID: 15184896]
[122]
Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002; 3(7): 673-80.
[http://dx.doi.org/10.1038/ni805] [PMID: 12055625]
[123]
Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001; 19(1): 423-74.
[http://dx.doi.org/10.1146/annurev.immunol.19.1.423] [PMID: 11244043]
[124]
Yamanaka K, Tanaka M, Tsutsui H, et al. Skin-specific caspase-1-transgenic mice show cutaneous apoptosis and pre-endotoxin shock condition with a high serum level of IL-18. J Immunol 2000; 165(2): 997-1003.
[http://dx.doi.org/10.4049/jimmunol.165.2.997] [PMID: 10878376]
[125]
Hansson L, Bäckman A, Ny A, et al. Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: A model for chronic itchy dermatitis. J Invest Dermatol 2002; 118(3): 444-9.
[http://dx.doi.org/10.1046/j.0022-202x.2001.01684.x] [PMID: 11874483]
[126]
Zhang JY. Animal Models of Skin Disorders. In: Animal Models for the Study of Human Disease. Academic Press 2017; pp. 357-75.
[http://dx.doi.org/10.1016/B978-0-12-809468-6.00015-2]
[127]
Barton D. HogenEsch H, Weih F. Mice lacking the transcription factor RelB develop T cell-dependent skin lesions similar to human atopic dermatitis. Eur J Immunol 2000; 30(8): 2323-32.
[http://dx.doi.org/10.1002/1521-4141(2000)30:8<2323:AID-IMMU2323>3.0.CO;2-H] [PMID: 10940923]
[128]
Tsukuba T, Okamoto K, Okamoto Y, et al. Association of cathepsin E deficiency with development of atopic dermatitis. J Biochem 2003; 134(6): 893-902.
[http://dx.doi.org/10.1093/jb/mvg216] [PMID: 14769879]
[129]
Marsella R, Girolomoni G. Canine models of atopic dermatitis: A useful tool with untapped potential. J Invest Dermatol 2009; 129(10): 2351-7.
[http://dx.doi.org/10.1038/jid.2009.98] [PMID: 19516261]
[130]
Marsella R, Olivry T. Animal models of atopic dermatitis. Clin Dermatol 2003; 21(2): 122-33.
[http://dx.doi.org/10.1016/S0738-081X(02)00369-3] [PMID: 12706330]
[131]
Boyera N, Cavey D, Bouclier M, et al. Repeated application of dinitrochlorobenzene to the ears of sensitized guinea pigs: A preliminary characterization of a potential new animal model for contact eczema in humans. Skin Pharmacol 1992; 5(3): 184-8.
[http://dx.doi.org/10.1159/000211036] [PMID: 1445708]
[132]
Pandey K. Nimisha. An Overview on Promising Nanotechnological Approaches for the Treatment of Psoriasis. Recent Pat Nanotechnol 2020; 14(2): 102-18.
[http://dx.doi.org/10.2174/1872210514666200204124130] [PMID: 32013854]
[133]
Mohan C, Puranik S, Sagar P, Sreenivasa S, Rao MC. Patents—An Important Tool for Pharmaceutical Industry. J PHARMACEUTICS & NANOTECH 2014; 2: 12-3.
[134]
Machler BC, Jacob SE. Method for treating allergic contact dermatitis. United States patent application US 16/688,826, 2020.
[135]
Bo Z. Liquid shampoo for treating seborrheic dermatitis. China. CN 110812268 A, 2020.
[136]
Yarbrough WM. Method for treating urushiol induced contact dermatitis. United States patent US 10,561,626, 2020.
[137]
Schlinger R, Sheskin T, Rosenberger V. Topical montelukast for treatment of atopic dermatitis. United States patent US 10,548,837, 2020.
[138]
Lee DK, Hong SW, Lee H, Yu D, Eom J. Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1. United States patent US 10,358,648, 2019.
[139]
Yu-Geun K. A composition for prevention or improvement of atopic dermatitis containing a herbal complex extract. Korea. KR 20190086317 A, 2019.
[140]
Schwendeman A, Cohen M, Subramanian C, et al. Compositions and methods for disease treatment using nanoparticle delivered compounds. United States patent US 10,220,046, 2019.
[141]
Kim Y, Yoo J, Kim G, et al. Composition for preventing, improving or treating atopic dermatitis comprising juice of radish root as effective component. South Korea. KR20180128602A, 2018.
[142]
Lang C, Heilmann A, Veen M, et al. Methods and means for protecting the skin against pathogenic microorganisms. United States patent application US 15/247,001, 2017.
[143]
Endo K. Method for treating dermatitis and improving skin texture using natriuretic peptides. United States patent US 9,358,269, 2016.
[144]
Katas H, Mohd AMCI, Sahudin S, Buang F. Chitosan-based skintargeted nanoparticle drug delivery system and method WO 2015072846 A1, 2015.
[145]
Harris TJ, Kim AAC. Targeted delivery of nanoparticles to skin surface. WO 2015031189 A1, 2015.
[146]
Jensen LB, Petersson K. Composition comprising lipid nanoparticles and a corticosteroid or vitamin d derivative. United States patent application US 14/006,890, 2014.
[147]
Ostertag EM, Tumeh PC, Ghoroghchian PP. Compositions and methods for treating or preventing immuno-inflammatory disease. United States patent application US 13/582,736, 2013.
[148]
Ford SB. Composition and Method for the Topical Treatment of Dermatitis. United States patent application US 12/844,770, 2012.
[149]
Liversidge G, Jenkins S, Bosch HW, Wertz CF. Nanoparticulate corticosteroid and antihistamine formulations methods of making, and methods of administering thereof. United States patent US 8,003,127, 2011.
[150]
Keck C. Compositions containing lipid micro- or nanoparticles for the enhancement of the dermal action of solid particles. WO 2010051918 A2, 2010.

Rights & Permissions Print Cite
Article Metrics
15
1
© 2024 Bentham Science Publishers | Privacy Policy